Cellares secures new funding, partnerships and FDA recognition as it prepares for commercial-scale cell therapy manufacturing ...
TScan (TCRX) stock outlook \| earnings expectations and sector performance remain in focus. TScan Therapeutics Inc. (TCRX) ...
Detailed price information for Tscan Therapeutics Inc (TCRX-Q) from The Globe and Mail including charting and trades.
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101 TSC-101 continues to be ...
Company remains on track to enroll their first patient in the Phase 3 ALLOHA-2™ study of TSC-101 this month Company to host virtual KOL event featuring Ran Reshef, M.D., M.Sc., today, June 22, at 8:30 ...
Collaboration will apply Cellares' fully automated Cell Shuttle® and Cell Q™ platforms to TScan’s lead TCR-T therapy candidate TSC-101 as a potentially scalable and cost-efficient path to ...
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago. These figures are ...
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2™) planned for the second quarter of ...
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago. These ...
TScan Therapeutics operates in the U.S. Small & Mid Cap Biotechnology sector, concentrating on innovative therapies for both hematological malignancies and solid tumors. The company’s primary focus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results